FDA Inspection
Cadila Pharmaceuticals LimitedCadila Pharmaceuticals Limited – FDA Inspection, May 3, 2018
Record Details
This FDA Inspection record concerns Cadila Pharmaceuticals Limited, with an inspection on May 3, 2018, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 63f78d34-ad1d-4b85-87a0-067d7502a5cd
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1052117
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 211.165(a)Testing and release for distribution
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Cadila Pharmaceuticals Limited
7| Date | Classification | Office | Project area |
|---|---|---|---|
| September 26, 2025 | NAI | Bioresearch Monitoring | |
| April 7, 2023 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 17, 2022 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| February 14, 2020 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| July 14, 2017 | Not classified | Office of Inspections and Investigations |
Other documents for Cadila Pharmaceuticals Limited
- FDA Inspection 1293740 - 2025-09-26
- FDA Inspection 1205061 - 2023-04-07
- FDA Inspection 1173461 - 2022-06-17
- FDA Inspection 1120482 - 2020-02-14
- FDA Inspection 1019141 - 2017-07-14
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.